search
Back to results

Endotype-Targeted Therapy to Rescue OSA Patients Struggling With CPAP Adherence (TOP-CPAP) (TOP-CPAP)

Primary Purpose

Obstructive Sleep Apnea

Status
Not yet recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Eszopiclone 2 mg
Placebo
Sponsored by
University of California, San Diego
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obstructive Sleep Apnea focused on measuring Obstructive Sleep Apnea, OSA, Continuous Positive Airway Pressure, CPAP, Adherence, Eszopiclone, Endotype, Arousal Threshold

Eligibility Criteria

21 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Ages 21-65 years old Body Mass Index <32 kg/m^2 Physician diagnosis of OSA (AHI β‰₯ 10) based on a clinical sleep study within the past 2 years (subjects who report a history of sleep apnea but do not have a sleep study report from the past 2 years available will be offered an overnight home sleep apnea test to verify OSA diagnosis) AHI>5/h on the overnight research sleep study #1 Subject had the opportunity to use CPAP for at least 1 month Continuous positive airway pressure (CPAP) data can be queried remotely and shows usage 0.5-4h/night (based on most recent 30 day period) Interest to continue trying CPAP Exclusion Criteria: "SAVE CPAP Side Effect Score" >3 (1 point for each: dry mouth, nasal symptoms, CPAP pressure intolerance, claustrophobia, noise problems, soreness/skin irritation, mask fit/leak problems) Any high-risk features: Epworth sleepiness score β‰₯18, safety-critical profession (e.g., commercial driver), prior sleep-related car accident, substantial hypoxemia during sleep [SpO2<70% for >5min] or awake [SpO2<92%] Any uncontrolled medical/psychiatric condition, or safety concern based on MD judgment Pregnancy/Breastfeeding (current or planned during the next month) Inability to complete study procedures, such as questionnaires that are only available/validated in English Other known untreated sleep fragmenting disorder, such as periodic limb movement disorder, or narcolepsy Unwilling or unable to withhold CPAP during polysomnography Presence of tracheostomy Hospitalization within the past 90 days Allergy to the study drug Regular use of opioids, or benzodiazepines Chronically using study drug or other hypnotic Significant circadian rhythm disorder or sleepwalking as an adult Active illicit substance use or >3 oz nightly alcohol use Prisoners Cognitive impairment, unable to provide consent, or unable to carry out research procedures Safety concern based on MD judgment

Sites / Locations

  • UC San Diego; Altman Clinical and Translational Research Institute Building

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Eszopiclone

Placebo

Arm Description

Subjects will be asked to take their study drugs nightly at bedtime and use their CPAP during sleep as much as possible

Subjects will be asked to take their study drugs nightly at bedtime and use their CPAP during sleep as much as possible

Outcomes

Primary Outcome Measures

Mean use per night of continuous positive airway pressure (CPAP)
Based on device recorded usage

Secondary Outcome Measures

Alternative measures of CPAP usage
E.g. percentage of nights with CPAP >4h
Response Speed
Based on 10-minute Psychomotor vigilance task (PVT)
Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance (SDA) instrument
Based on response pattern scoring, the PROMIS 8-item SDA score will be converted into a T-score with a mean of 50 (reflecting the average for the United States general population) and a standard deviation of 10. Higher t-scores reflect greater sleep disturbance.
Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment (SRI) instrument
Based on response pattern scoring, the PROMIS 8-item SRI score will be converted into a T-score with a mean of 50 (reflecting the average for the United States general population) and a standard deviation of 10. Higher t-scores reflect greater sleep-related impairment.
Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue instrument
Based on response pattern scoring, the PROMIS 8-item Fatigue score will be converted into a T-score with a mean of 50 (reflecting the average for the United States general population) and a standard deviation of 10. Higher t-scores reflect greater sleep-related impairment.
Epworth Sleepiness Scale (ESS)
The ESS is an 8-item instrument assessing the likelihood of dozing off in 8 different situations with points for each item ranging from 0 to 3 (0 = would never doze off; 3 = high chance of dozing off). The points for each item are summed up, thus the total score ranges from 0 to 24, with higher ESS scores indicating greater sleepiness.
Apnea Hypopnea Index
The AHI is a measure of sleep apnea severity and is defined as the number of apneas and hypopneas per hour of sleep.
Mean Blood Pressure (mmHg)
Average of two in-office blood pressure measurements

Full Information

First Posted
June 17, 2023
Last Updated
July 10, 2023
Sponsor
University of California, San Diego
Collaborators
American Academy of Sleep Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT05951023
Brief Title
Endotype-Targeted Therapy to Rescue OSA Patients Struggling With CPAP Adherence (TOP-CPAP)
Acronym
TOP-CPAP
Official Title
Endotype-Targeted Therapy to Rescue OSA Patients Struggling With CPAP Adherence (TOP-CPAP): a Pilot Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
August 1, 2023 (Anticipated)
Primary Completion Date
November 30, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, San Diego
Collaborators
American Academy of Sleep Medicine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
More than 10% of the US population have obstructive sleep apnea (OSA). Standard of care is therapy with CPAP (continuous positive airway pressure) which virtually eliminates OSA. However, most patients use CPAP only for part of the night (4-5hours) and about 50% patients discontinue CPAP long-term. Alternative therapies are limited, thus many OSA patients remain at risk of OSA sequelae (e.g. sleepiness, memory issues, high blood pressure, etc.). Importantly, different patients get OSA for different reasons, and recent data show that some of the underlying causes of OSA ("endotypes") such as having a low arousal threshold (i.e. waking up easily) are associated with lower CPAP adherence. Using a randomized controlled trial design, this will be the first study using a targeted intervention to manipulate the underlying OSA causes (i.e., giving a safe hypnotic to patients with OSA to increase the arousal threshold) to test the hypothesis that endotype-targeted therapy increases CPAP-adherence in patients who have low but continued CPAP usage. Ultimately, this strategy may improve the care and outcomes of millions of undertreated OSA patients.
Detailed Description
This double-blind, randomized, placebo-controlled, single-center, phase II trial, will test if endotype-targeted drug therapy increases CPAP adherence. Patients with low CPAP adherence (i.e. CPAP use 0.5-4h/night) will be randomized in parallel to CPAP+Eszopiclone vs CPAP+Placebo for 2 weeks. The primary outcome is mean TimeOnCPAP/night on days 2-14 after initiation of study drugs. Aim 1: To test the effect of eszopiclone on CPAP usage in unselected OSA patients with low CPAP adherence. Hypothesis 1: Eszopiclone improves CPAP usage more than placebo. Aim 2: To test the effect of eszopiclone on CPAP usage in OSA patients with a low vs a high arousal threshold (ArTH) endotype. Hypothesis 2: Eszopiclone improves CPAP usage substantially more in OSA patients with a low vs a high ArTH. Further, this study will explore the mechanisms through which eszopiclone may affect CPAP usage, the effect of eszopiclone on underlying sleep apnea severity, and if the intervention and its potential effects on adherence translate into changes in clinically important outcomes (i.e., vigilance and sleepiness).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obstructive Sleep Apnea
Keywords
Obstructive Sleep Apnea, OSA, Continuous Positive Airway Pressure, CPAP, Adherence, Eszopiclone, Endotype, Arousal Threshold

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Randomized, double-blind, placebo-controlled, parallel trial
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Eszopiclone
Arm Type
Experimental
Arm Description
Subjects will be asked to take their study drugs nightly at bedtime and use their CPAP during sleep as much as possible
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Subjects will be asked to take their study drugs nightly at bedtime and use their CPAP during sleep as much as possible
Intervention Type
Drug
Intervention Name(s)
Eszopiclone 2 mg
Other Intervention Name(s)
Lunesta
Intervention Description
Eszopiclone tablet (encapsulated)
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Sugar capsule manufactured to match encapsulated Eszopiclone
Primary Outcome Measure Information:
Title
Mean use per night of continuous positive airway pressure (CPAP)
Description
Based on device recorded usage
Time Frame
days 2-14 after initiation of study drugs
Secondary Outcome Measure Information:
Title
Alternative measures of CPAP usage
Description
E.g. percentage of nights with CPAP >4h
Time Frame
days 2-14 after initiation of study drugs
Title
Response Speed
Description
Based on 10-minute Psychomotor vigilance task (PVT)
Time Frame
days 2-14 after initiation of study drugs
Title
Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance (SDA) instrument
Description
Based on response pattern scoring, the PROMIS 8-item SDA score will be converted into a T-score with a mean of 50 (reflecting the average for the United States general population) and a standard deviation of 10. Higher t-scores reflect greater sleep disturbance.
Time Frame
days 2-14 after initiation of study drugs
Title
Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment (SRI) instrument
Description
Based on response pattern scoring, the PROMIS 8-item SRI score will be converted into a T-score with a mean of 50 (reflecting the average for the United States general population) and a standard deviation of 10. Higher t-scores reflect greater sleep-related impairment.
Time Frame
days 2-14 after initiation of study drugs
Title
Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue instrument
Description
Based on response pattern scoring, the PROMIS 8-item Fatigue score will be converted into a T-score with a mean of 50 (reflecting the average for the United States general population) and a standard deviation of 10. Higher t-scores reflect greater sleep-related impairment.
Time Frame
days 2-14 after initiation of study drugs
Title
Epworth Sleepiness Scale (ESS)
Description
The ESS is an 8-item instrument assessing the likelihood of dozing off in 8 different situations with points for each item ranging from 0 to 3 (0 = would never doze off; 3 = high chance of dozing off). The points for each item are summed up, thus the total score ranges from 0 to 24, with higher ESS scores indicating greater sleepiness.
Time Frame
days 2-14 after initiation of study drugs
Title
Apnea Hypopnea Index
Description
The AHI is a measure of sleep apnea severity and is defined as the number of apneas and hypopneas per hour of sleep.
Time Frame
day1 of study drugs
Title
Mean Blood Pressure (mmHg)
Description
Average of two in-office blood pressure measurements
Time Frame
day 14 after initiation of study drugs
Other Pre-specified Outcome Measures:
Title
Sleep Apnea Traits with special focus on arousal threshold
Description
Quantified from routine polysomnography data.
Time Frame
day1 of study drugs
Title
Average total sleep time per night
Description
Based on actigraphy
Time Frame
days 2-14 after initiation of study drugs

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Ages 21-65 years old Body Mass Index <32 kg/m^2 Physician diagnosis of OSA (AHI β‰₯ 10) based on a clinical sleep study within the past 2 years (subjects who report a history of sleep apnea but do not have a sleep study report from the past 2 years available will be offered an overnight home sleep apnea test to verify OSA diagnosis) AHI>5/h on the overnight research sleep study #1 Subject had the opportunity to use CPAP for at least 1 month Continuous positive airway pressure (CPAP) data can be queried remotely and shows usage 0.5-4h/night (based on most recent 30 day period) Interest to continue trying CPAP Exclusion Criteria: "SAVE CPAP Side Effect Score" >3 (1 point for each: dry mouth, nasal symptoms, CPAP pressure intolerance, claustrophobia, noise problems, soreness/skin irritation, mask fit/leak problems) Any high-risk features: Epworth sleepiness score β‰₯18, safety-critical profession (e.g., commercial driver), prior sleep-related car accident, substantial hypoxemia during sleep [SpO2<70% for >5min] or awake [SpO2<92%] Any uncontrolled medical/psychiatric condition, or safety concern based on MD judgment Pregnancy/Breastfeeding (current or planned during the next month) Inability to complete study procedures, such as questionnaires that are only available/validated in English Other known untreated sleep fragmenting disorder, such as periodic limb movement disorder, or narcolepsy Unwilling or unable to withhold CPAP during polysomnography Presence of tracheostomy Hospitalization within the past 90 days Allergy to the study drug Regular use of opioids, or benzodiazepines Chronically using study drug or other hypnotic Significant circadian rhythm disorder or sleepwalking as an adult Active illicit substance use or >3 oz nightly alcohol use Prisoners Cognitive impairment, unable to provide consent, or unable to carry out research procedures Safety concern based on MD judgment
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Pamela DeYoung, RPSGT
Phone
858 246 2183
Email
sleepresearch@health.ucsd.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christopher N Schmickl, MD, PhD
Organizational Affiliation
University of California, San Diego
Official's Role
Principal Investigator
Facility Information:
Facility Name
UC San Diego; Altman Clinical and Translational Research Institute Building
City
La Jolla
State/Province
California
ZIP/Postal Code
92121
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Endotype-Targeted Therapy to Rescue OSA Patients Struggling With CPAP Adherence (TOP-CPAP)

We'll reach out to this number within 24 hrs